Thiogenesis Announces European Consulting and Investor Relations Agreement

Core Viewpoint - Thiogenesis Therapeutics, Corp. has entered into a consulting and investor relations agreement with Bull Markets Media GmbH to enhance its shareholder base and expand its network in Europe [1][2]. Group 1: Agreement Details - The consulting fee for the agreement is C$60,000, with 50$0.64 each for a term of 3 years, with options vesting in tranches [3]. - The agreement has a duration of twelve months and can be renewed annually for up to two additional years [3]. Group 2: Company Overview - Thiogenesis Therapeutics is a clinical-stage biopharmaceutical company focused on developing sulfur-containing prodrugs aimed at treating serious pediatric diseases with unmet medical needs [5]. - The company utilizes a streamlined 505 (b)(2) regulatory pathway in the US and a hybrid system in Europe for regulatory submissions, which allows for the use of existing safety data [5]. - Initial target indications for the company's products include Mitochondrial Encephalopathy Lactic Acidosis and Stroke (MELAS), Leigh syndrome, Rett syndrome, and pediatric MASH [5]. Group 3: Regulatory and Compliance - The agreement with the consultant is subject to acceptance by the TSX Venture Exchange [4]. - The company has received final acceptance from the TSXV for its investor relations contract with Triomphe Holdings Ltd. [4].